207_Combined course Presentations

Alternative drugs: CILENGITIDE (CENTRIC/EORTC 26071)

 Cilengitide is a selective integrin inhibitor

 Data from phase I-II studies suggest that it has antitumor activity

in association with TMZ (particularly in tumors with methylated

MGMT promoter).

 545 patients randomized to receive either CILENGITIDE

“The addition of Cilengitide to Stupp regimen did not improve outcomes”

(272) or PLACEBO (273) in addition to Stupp regimen

Stupp R. et al. Lancet Oncol 2014;15